Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,717.60
(
-0.33%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
110.24
(
3.43%
)
Bitcoin
70,240.37
(
-1.41%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 156902

Thursday, 10/06/2016 10:02:01 AM

Thursday, October 06, 2016 10:02:01 AM

Post# of 257257
TEVA, Celltrion ink FoB collaboration for Rituxan/Herceptin in US/Canada:

http://finance.yahoo.com/news/teva-celltrion-announce-exclusive-biosimilar-120000044.html

This is essentially a booby price for TEVA, who has been actively searching for a global FoB partner. Celltrion’s FoB programs for Rituxan and Herceptin were returned by PFE in 2015 as a consequence of PFE’s merger with HSP (http://www.fiercebiotech.com/r-d/pfizer-cuts-some-biosimilar-ties-celltrion-after-its-17b-hospira-deal ).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now